|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0644 - 0.0644|
|52 Week Range||0.0600 - 0.1700|
|Beta (3Y Monthly)||2.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced that it entered into an amended agreement related to its existing credit facility with SWK Funding LLC (“SWK”) and that it received a waiver letter from SWK related to certain financial covenants for Q3 2019. The nature of the amendment is to set the minimum threshold for Consolidated Unencumbered Liquid Assets required to be maintained by the Company. In connection with the amendment, Acerus agreed to reprice 5,331,563 outstanding common shares purchase warrants currently held by SWK that were issued with the signing of the credit agreement in 2018 (the “Original Warrants”).
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we...
TORONTO, July 30, 2019 /PRNewswire/ -- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) today announced that it will be taking an expanded role in the commercialization of NATESTO® in the U.S. The company has entered into an amended and restated licensing agreement with Aytu BioScience, Inc. (AYTU), which will, upon closing, move the partnership from an out-license model to a co-promotion arrangement that the companies believe will leverage their collective product, marketplace and Men's Health experience to capture a significant share of the U.S. market for NATESTO®. Under the terms of the new agreement, Aytu returns the NDA for NATESTO® in the U.S. back to Acerus. Going forward Acerus will assume all regulatory and clinical responsibilities and costs for the product in the U.S. Acerus will take on a more expansive role in matters such as U.S. marketing, reimbursement and medical strategy as part of the companies' joint commercialization committee, and will launch a specialist sales force focused on urologists and endocrinologists (Acerus Sales Channel).
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) today announced that it entered into an amended agreement related to its existing credit facility with SWK Funding LLC (“SWK”). The nature of the amendment is to set the minimum threshold for Consolidated Unencumbered Liquid Assets required to be maintained by the Company. This level will be set at US$1 million at all times up until July 31, 2019 and either (i) US$2 million at all times thereafter unless the Company can demonstrate that it has raised a minimum of US$5 million in gross equity or subordinated debt (or any combination thereof) between June 25, 2019 and July 31, 2019 (the “Subsequent Raise”) or (ii) US$1 million at all times thereafter if the Subsequent Raise is completed.
TORONTO , June 27, 2019 /CNW/ - Acerus Pharmaceuticals Corporation ("Acerus") (ASP.TO) today announced the voting results from its annual meeting of shareholders held on June 27, 2019 in Toronto, Ontario . The six (6) candidates nominated for election to the Acerus board of directors and listed in Acerus' management information circular dated May 15, 2019 , were elected by a majority of the shareholders present in person or represented by proxy at the meeting. Acerus announced today that its shareholders have approved the re‐appointment of PricewaterhouseCoopers LLP as the Auditor of Acerus to hold office until the next annual meeting of shareholders.
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that Health Canada has completed the initial screening process for the previously announced New Drug Submission (“NDS”) for avanafil. The dossier is now in active review by Health Canada and Acerus expects review completion and, if approved, Notice of Compliance issuance to be in early Q2 of 2020. Avanafil, a treatment for erectile dysfunction (“ED”), is a new, second generation PDE5 inhibitor, which has increased receptor specificity for fast onset of action and lower off-target side effects.
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) today announced that it has reached a mutual agreement with Innovus Pharmaceuticals, Inc. (INNV) (“Innovus Pharma”), a California-based specialty pharmaceutical company, to terminate the exclusive distributor and license agreement granting Acerus the rights to commercialize UriVarx® in Canada. “The termination of this license agreement with Innovus is consistent with our renewed strategic focus on prescription products and men’s health,” said Ed Gudaitis, President and Chief Executive Officer of Acerus.
OTCQB:ASPCF) announced today that it has signed a patent license agreement (the “PLA”) with the University of Texas at Austin for technology related to the nasal administration of testosterone. The newly patented, aqueous-based, nasal delivery technology was developed by Robert Josephs, a UT Austin Professor of Clinical and Social Psychology, and Craig Herman, a Doctor of Pharmacy at MedCara Pharmaceuticals in Conrad, Iowa.